WO2000032239A1 - Hapten-carrier conjugates for treating and preventing nicotine addiction - Google Patents
Hapten-carrier conjugates for treating and preventing nicotine addiction Download PDFInfo
- Publication number
- WO2000032239A1 WO2000032239A1 PCT/US1999/028272 US9928272W WO0032239A1 WO 2000032239 A1 WO2000032239 A1 WO 2000032239A1 US 9928272 W US9928272 W US 9928272W WO 0032239 A1 WO0032239 A1 WO 0032239A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nicotine
- hapten
- antibody
- carrier
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/816—Alkaloids, amphetamines, and barbiturates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Addiction (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL349012A PL199253B1 (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugate, antibody, antibody functional fragment, complex containing antibody, method for the manufacture of antibody as well as vaccine compound |
JP2000584928A JP4971542B2 (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier complex for the treatment and prevention of nicotine addiction |
NZ512103A NZ512103A (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
IL14347499A IL143474A0 (en) | 1998-12-01 | 1999-12-01 | Haptene-carrier conjugates and vaccines containing the same |
CA2352765A CA2352765C (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
EA200100610A EA004956B1 (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates, antibody and process for producing thereof, functional fragment of the antibody, a kit for determining the presence of nicotine in a sample, a vaccine composition and method of preventing or treating nicotine addiction |
AT99964009T ATE279211T1 (en) | 1998-12-01 | 1999-12-01 | HAPTEN CARRIER CONJUGATES FOR THE TREATMENT AND PREVENTION OF NICOTINE DEPENDENCE |
BR9915852-3A BR9915852A (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugate for treatment and prevention of nicotine addiction |
MXPA01005511A MXPA01005511A (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction. |
EP99964009A EP1135166B9 (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
AU20335/00A AU763001B2 (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
HU0104365A HUP0104365A3 (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction, vaccines and pharmaceutical compositions comprising thereof, antibody produced inresponse to the conjugate, and their use |
DE69921178T DE69921178T2 (en) | 1998-12-01 | 1999-12-01 | HAPTEN-CARRIER CONJUGATES FOR TREATING AND PREVENTING NICOTINE DEPENDENCE |
MEP-342/08A MEP34208A (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
NO20012589A NO331998B1 (en) | 1998-12-01 | 2001-05-25 | Nicotine-bound haptenic carrier conjugates and used as a drug, antibody prepared in response to these conjugates, antibody functional fragments, antibody preparation method, vaccine composition comprising the haptenic carrier conjugates, the use of haptenic drug conjugates, and nicotine presence assays. for the treatment of nicotine addiction. |
IL143474A IL143474A (en) | 1998-12-01 | 2001-05-31 | Hapten-carrier conjugates and vaccines containing the same |
HK02102329.6A HK1042428B (en) | 1998-12-01 | 2002-03-26 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
HK02104914.3A HK1043061B (en) | 1998-12-01 | 2002-06-29 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/201,800 | 1998-12-01 | ||
US09/201,800 US6232082B1 (en) | 1998-12-01 | 1998-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000032239A1 true WO2000032239A1 (en) | 2000-06-08 |
WO2000032239A9 WO2000032239A9 (en) | 2002-08-22 |
Family
ID=22747358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/028272 WO2000032239A1 (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
Country Status (26)
Country | Link |
---|---|
US (7) | US6232082B1 (en) |
EP (3) | EP2324855A1 (en) |
JP (2) | JP4971542B2 (en) |
KR (1) | KR100656836B1 (en) |
CN (2) | CN100586481C (en) |
AT (1) | ATE279211T1 (en) |
AU (1) | AU763001B2 (en) |
BR (1) | BR9915852A (en) |
CA (1) | CA2352765C (en) |
DE (1) | DE69921178T2 (en) |
DK (1) | DK1135166T3 (en) |
EA (1) | EA004956B1 (en) |
ES (1) | ES2229800T3 (en) |
HK (3) | HK1042428B (en) |
HU (1) | HUP0104365A3 (en) |
IL (2) | IL143474A0 (en) |
ME (1) | MEP34208A (en) |
MX (1) | MXPA01005511A (en) |
NO (1) | NO331998B1 (en) |
NZ (1) | NZ512103A (en) |
PL (1) | PL199253B1 (en) |
PT (1) | PT1135166E (en) |
RS (1) | RS51273B (en) |
TR (1) | TR200102411T2 (en) |
WO (1) | WO2000032239A1 (en) |
ZA (1) | ZA200104477B (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002058635A2 (en) * | 2001-01-26 | 2002-08-01 | The Scripps Research Institute | Nicotine immunogens and antibodies and uses thereof |
WO2003082329A2 (en) * | 2002-03-01 | 2003-10-09 | The Board Of Regents Of The University Of Nebraska | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
EP1638597A2 (en) * | 2003-06-16 | 2006-03-29 | GlaxoSmithKline Biologicals S.A. | Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines |
EP1849780A1 (en) * | 2006-04-21 | 2007-10-31 | De Staat der Nederlanden, vert. door de minister van VWS | Vaccine against nicotine addiction |
EP1854478A1 (en) * | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
EP1963308A2 (en) * | 2005-11-28 | 2008-09-03 | Nabi Biopharmaceuticals | Method for making nicotine hapten |
WO2011127989A1 (en) | 2010-04-15 | 2011-10-20 | Glaxosmithkline Biologicals S.A. | Nicotine conjugate vaccine |
WO2011151807A1 (en) | 2010-06-04 | 2011-12-08 | Pfizer Vaccines Llc | Conjugates for the prevention or treatment of nicotine addiction |
WO2012074773A1 (en) * | 2010-11-18 | 2012-06-07 | Nabi Biopharmceuticals | Personalized drug treatment methods |
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
US9080014B2 (en) | 2006-05-15 | 2015-07-14 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2015173685A1 (en) | 2014-05-16 | 2015-11-19 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
CN106458971A (en) * | 2014-05-19 | 2017-02-22 | 斯克利普斯研究院 | Enantiopure Haptens For Nicotine Vaccine Development |
WO2019036419A1 (en) | 2017-08-15 | 2019-02-21 | Kalnik Matthew W | Novel nicotine-binding antibodies |
WO2019236665A1 (en) | 2018-06-06 | 2019-12-12 | Antidote Therapeutics, Inc. | Methods for improving circulation and treating cardiovascular disease |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020032316A1 (en) * | 1995-03-31 | 2002-03-14 | Cantab Pharmaceuticals Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US6232082B1 (en) * | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
SE521512C2 (en) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Device for administering a substance to the front of an individual's oral cavity |
US20030148260A1 (en) * | 2001-08-07 | 2003-08-07 | Bernard Levin | Method of diagnosing colorectal adenomas and cancer using proton maggnetic resonance spectroscopy |
CN101574518B (en) | 2002-07-18 | 2012-08-22 | 赛托斯生物技术公司 | Hapten-carrier conjugates and uses thereof |
US20040115244A1 (en) * | 2002-12-17 | 2004-06-17 | Holgate Eric Jamison | Methods and compositions for nicotine replacement therapy |
EP1578422B1 (en) * | 2002-12-20 | 2007-04-11 | NicoNovum AB | A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material |
WO2005040338A2 (en) * | 2003-05-21 | 2005-05-06 | The Scripps Research Institute | Constrained alkaloid immunogens and antibodies and uses thereof |
US7220842B2 (en) * | 2004-04-05 | 2007-05-22 | Dade Behring Inc. | Immunoassays for buprenorphine and norbuprenorphine |
US7678551B2 (en) * | 2004-10-25 | 2010-03-16 | Seradyn, Inc. | Immunoassays for lamotrigine |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
WO2006091796A2 (en) * | 2005-02-22 | 2006-08-31 | Acucela, Inc. | Compositions and methods for diagnosing and treating retinal diseases |
US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
US7547712B2 (en) * | 2006-02-27 | 2009-06-16 | Nabi Biopharmaceuticals | Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women |
WO2007104573A2 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
US20110052697A1 (en) * | 2006-05-17 | 2011-03-03 | Gwangju Institute Of Science & Technology | Aptamer-Directed Drug Delivery |
WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
WO2008019142A2 (en) * | 2006-08-04 | 2008-02-14 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
WO2008124634A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
EP2144600A4 (en) * | 2007-04-04 | 2011-03-16 | Massachusetts Inst Technology | Poly (amino acid) targeting moieties |
EP2319867A1 (en) * | 2007-11-29 | 2011-05-11 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
EP2065398A1 (en) * | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
CN102056624A (en) * | 2008-06-04 | 2011-05-11 | 康奈尔大学 | Vaccines for prevention and treatment of addiction |
US8232072B2 (en) * | 2008-06-13 | 2012-07-31 | Nabi Biopharmaceuticals | Smoking cessation kit and method |
US20110136209A1 (en) * | 2008-08-08 | 2011-06-09 | Benjamin Martin | Process for the preparation of nicotine-based haptens |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
EP2376107B1 (en) | 2008-12-09 | 2014-05-21 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
WO2011014679A1 (en) | 2009-07-31 | 2011-02-03 | Nabi Biopharmaceuticals | Method and kit for treating nicotine addiction |
CN107715118A (en) * | 2009-08-26 | 2018-02-23 | 西莱克塔生物科技公司 | The composition of inducing T cell auxiliary |
EP2477974A2 (en) * | 2009-09-14 | 2012-07-25 | The Scripps Research Institute | Nicotine haptens, immunoconjugates and their uses |
US20110182831A1 (en) * | 2010-01-25 | 2011-07-28 | Aradigm Corporation | Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use |
US9682133B2 (en) | 2010-03-17 | 2017-06-20 | Cornell University | Disrupted adenovirus-based vaccine against drugs of abuse |
WO2011123042A1 (en) * | 2010-04-01 | 2011-10-06 | Independent Pharmaceutica Ab | Vaccination procedure and products for use therein |
NO2575876T3 (en) | 2010-05-26 | 2018-05-05 | ||
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | Modified nicotinic compounds and related methods |
WO2012099717A1 (en) * | 2011-01-04 | 2012-07-26 | National Jewish Health | Leukotrienes and asthma exacerbation risk |
CA2834734A1 (en) | 2011-04-04 | 2012-10-11 | University Of Iowa Research Foundation | Methods of improving vaccine immunogenicity |
CA2843274A1 (en) | 2011-07-29 | 2013-02-07 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
WO2013130393A1 (en) | 2012-02-28 | 2013-09-06 | Cornell University | Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation |
WO2013154744A1 (en) * | 2012-04-13 | 2013-10-17 | Cornell University | Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction |
TWI600905B (en) * | 2012-09-21 | 2017-10-01 | 國立臺灣師範大學 | Methods for polymerization of haptens into immunogens |
CN104402992B (en) * | 2014-11-28 | 2018-09-18 | 杭州安旭科技有限公司 | A kind of synthetic method synthesizing hemp antigen and the application for synthesizing hemp antigen |
WO2016116477A1 (en) * | 2015-01-20 | 2016-07-28 | Universiteit Antwerpen | Neuregulin in the treatment of fibrotic disorders |
CN106496309A (en) * | 2016-11-24 | 2017-03-15 | 北京开景基因技术有限公司 | Microballoon antigen and preparation method thereof and the preparation method of anti-cotinine antibody |
AU2018283973A1 (en) | 2017-06-11 | 2020-01-16 | Molecular Express, Inc. | Methods and compositions for substance use disorder vaccine formulations and uses thereof |
CN108362891B (en) * | 2017-12-27 | 2020-09-25 | 北京勤邦生物技术有限公司 | Prednisone magnetic immuno-chemiluminescence detection kit and application thereof |
US11073296B2 (en) | 2018-03-09 | 2021-07-27 | Scot Matthew Duncan | High efficiency dehumidification system (HEDS) |
KR102237349B1 (en) | 2019-10-23 | 2021-04-07 | 한국과학기술연구원 | Pharmaceutical composition for the treatment or prevention of nicotine addiction and withdrawal comprising miRNA |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992003163A1 (en) * | 1990-08-22 | 1992-03-05 | Cerny Erich H | Vaccine and immunoserum against drugs of abuse |
WO1993023076A1 (en) * | 1992-05-20 | 1993-11-25 | The Johns-Hopkins University | Alternative receptor therapy |
WO1996030049A2 (en) * | 1995-03-31 | 1996-10-03 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy |
WO1998014216A2 (en) * | 1996-09-30 | 1998-04-09 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4375414A (en) | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
US3888886A (en) | 1972-06-08 | 1975-06-10 | Mobil Oil Corp | Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst |
US4045420A (en) | 1973-05-29 | 1977-08-30 | Syva Company | Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof |
US3888866A (en) | 1973-06-01 | 1975-06-10 | Syva Co | Nitrogen derivatives of benzoyl ecgonine |
US4053459A (en) | 1975-09-24 | 1977-10-11 | Hoffmann-La Roche Inc. | Antibody specific to methaqualone and its metabolites |
US4235864A (en) | 1978-04-10 | 1980-11-25 | Research Corporation | Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites |
US4376825A (en) | 1979-05-07 | 1983-03-15 | Syva Company | Enzyme amplification compounds for assays for androgens |
US4666837A (en) | 1982-05-24 | 1987-05-19 | Smithkline-Rit | DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits |
SU1123704A1 (en) | 1983-04-08 | 1984-11-15 | Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений | Method of obtaining conjugated antigens |
AU5444386A (en) | 1985-03-08 | 1986-09-11 | Baylor College Of Medicine | Anti-nicotine and anti-cotinine antibodies (monoclonal and polyclonal) |
US5019384A (en) | 1986-06-30 | 1991-05-28 | Massachusetts Institute Of Technology | Immunonodulating compositions and their use |
US4791067A (en) | 1987-06-25 | 1988-12-13 | Fisher Scientific Co. | Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent |
EP0311383B1 (en) | 1987-10-09 | 1993-10-06 | Ube Industries, Ltd. | Monoclonal antibody to methamphetamine, preparation of the same, assay method and assay kit of methamphetamine |
US5268276A (en) | 1988-09-16 | 1993-12-07 | Jan Holmgren | Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides |
EP0363041A1 (en) | 1988-09-21 | 1990-04-11 | Ube Industries, Ltd. | Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine |
GB9001694D0 (en) | 1990-01-25 | 1990-03-28 | Therapeutic Antibodies Inc | Immunogenic compositions |
US5674978A (en) | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
US5290784A (en) * | 1991-07-18 | 1994-03-01 | Yueqian Qu | Aconitane derivatives used as a medication to treat addiction |
US5233042A (en) | 1991-12-16 | 1993-08-03 | Biosite Diagnostics, Inc. | Cocaine derivatives |
US5283066A (en) | 1992-02-19 | 1994-02-01 | Development Center For Biotechnology | Method of stimulating an immune response by using a hapten |
DE4216133A1 (en) | 1992-05-15 | 1993-11-18 | Bissendorf Peptide Gmbh | Use of urodilatin in lung and bronchial diseases |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
DE69332637T2 (en) | 1993-03-04 | 2003-10-23 | Matsushita Electric Ind Co Ltd | Cocaine derivative, protein conjugate thereof, a hybridoma cell line producing a monoclonal antibody, process for producing the hybridoma cell line and the monoclonal antibody |
US5375414A (en) | 1993-10-04 | 1994-12-27 | Ford Motor Company | Automotive engine exhaust aftertreatment system including hydrocarbon adsorber with internal engine purge flow control |
EP0756629A1 (en) | 1994-04-08 | 1997-02-05 | Immunologic Pharmaceutical Corporation | Pharmaceutical formulations for treating japanese cedar pollen allergy |
US5510102A (en) | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5840307A (en) | 1995-03-31 | 1998-11-24 | Immulogic Pharmacuetical Corp. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation |
JP2001516567A (en) * | 1997-09-19 | 2001-10-02 | セレックス, インコーポレイテッド | Methods for improving antigen immunogenicity and antibody specificity |
US6232082B1 (en) * | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
-
1998
- 1998-12-01 US US09/201,800 patent/US6232082B1/en not_active Expired - Fee Related
-
1999
- 1999-12-01 TR TR2001/02411T patent/TR200102411T2/en unknown
- 1999-12-01 BR BR9915852-3A patent/BR9915852A/en not_active IP Right Cessation
- 1999-12-01 RS YUP-396/01A patent/RS51273B/en unknown
- 1999-12-01 PL PL349012A patent/PL199253B1/en not_active IP Right Cessation
- 1999-12-01 CA CA2352765A patent/CA2352765C/en not_active Expired - Fee Related
- 1999-12-01 MX MXPA01005511A patent/MXPA01005511A/en not_active IP Right Cessation
- 1999-12-01 HU HU0104365A patent/HUP0104365A3/en unknown
- 1999-12-01 WO PCT/US1999/028272 patent/WO2000032239A1/en active IP Right Grant
- 1999-12-01 ES ES99964009T patent/ES2229800T3/en not_active Expired - Lifetime
- 1999-12-01 EA EA200100610A patent/EA004956B1/en not_active IP Right Cessation
- 1999-12-01 EP EP10179154A patent/EP2324855A1/en not_active Withdrawn
- 1999-12-01 DE DE69921178T patent/DE69921178T2/en not_active Expired - Lifetime
- 1999-12-01 DK DK99964009T patent/DK1135166T3/en active
- 1999-12-01 KR KR1020017006805A patent/KR100656836B1/en not_active IP Right Cessation
- 1999-12-01 NZ NZ512103A patent/NZ512103A/en not_active IP Right Cessation
- 1999-12-01 AT AT99964009T patent/ATE279211T1/en active
- 1999-12-01 JP JP2000584928A patent/JP4971542B2/en not_active Expired - Fee Related
- 1999-12-01 IL IL14347499A patent/IL143474A0/en active IP Right Grant
- 1999-12-01 CN CN200510092438A patent/CN100586481C/en not_active Expired - Fee Related
- 1999-12-01 EP EP04024278A patent/EP1512414A1/en not_active Withdrawn
- 1999-12-01 CN CNB998139564A patent/CN1220521C/en not_active Expired - Fee Related
- 1999-12-01 AU AU20335/00A patent/AU763001B2/en not_active Ceased
- 1999-12-01 ME MEP-342/08A patent/MEP34208A/en unknown
- 1999-12-01 PT PT99964009T patent/PT1135166E/en unknown
- 1999-12-01 EP EP99964009A patent/EP1135166B9/en not_active Revoked
-
2001
- 2001-02-16 US US09/784,139 patent/US6518031B2/en not_active Expired - Fee Related
- 2001-05-25 NO NO20012589A patent/NO331998B1/en not_active IP Right Cessation
- 2001-05-31 ZA ZA200104477A patent/ZA200104477B/en unknown
- 2001-05-31 IL IL143474A patent/IL143474A/en not_active IP Right Cessation
-
2002
- 2002-03-26 HK HK02102329.6A patent/HK1042428B/en not_active IP Right Cessation
- 2002-06-29 HK HK02104914.3A patent/HK1043061B/en not_active IP Right Cessation
- 2002-12-30 US US10/330,676 patent/US6773891B2/en not_active Expired - Fee Related
-
2004
- 2004-08-03 US US10/909,841 patent/US7247502B2/en not_active Expired - Fee Related
-
2006
- 2006-11-06 HK HK06112172.9A patent/HK1091415A1/en not_active IP Right Cessation
-
2007
- 2007-07-20 US US11/780,742 patent/US7776620B2/en not_active Expired - Fee Related
-
2010
- 2010-07-14 US US12/836,165 patent/US8026109B2/en not_active Expired - Fee Related
- 2010-11-29 JP JP2010264835A patent/JP2011079849A/en active Pending
-
2011
- 2011-05-13 US US13/107,460 patent/US20110217320A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992003163A1 (en) * | 1990-08-22 | 1992-03-05 | Cerny Erich H | Vaccine and immunoserum against drugs of abuse |
WO1993023076A1 (en) * | 1992-05-20 | 1993-11-25 | The Johns-Hopkins University | Alternative receptor therapy |
WO1996030049A2 (en) * | 1995-03-31 | 1996-10-03 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy |
WO1998014216A2 (en) * | 1996-09-30 | 1998-04-09 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
Non-Patent Citations (1)
Title |
---|
GASTRO A ET AL: "CHARACTERIZATION OF ANTIBODIES TO NICOTINE", BIOCHEMICAL ARCHIVES,US,M.B.R. PRESS, INC, vol. 1, no. 3, 1 August 1985 (1985-08-01), pages 173 - 183, XP000616324, ISSN: 0749-5331 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002058635A3 (en) * | 2001-01-26 | 2003-03-20 | Scripps Research Inst | Nicotine immunogens and antibodies and uses thereof |
WO2002058635A2 (en) * | 2001-01-26 | 2002-08-01 | The Scripps Research Institute | Nicotine immunogens and antibodies and uses thereof |
WO2003082329A2 (en) * | 2002-03-01 | 2003-10-09 | The Board Of Regents Of The University Of Nebraska | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
WO2003082329A3 (en) * | 2002-03-01 | 2004-02-12 | Univ Nebraska | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
EP2277540A3 (en) * | 2003-06-16 | 2011-11-02 | GlaxoSmithKline Biologicals S.A. | Polyanionic polymer adjuvants for haemophilus influenza B saccharide vaccines |
EP1638597A2 (en) * | 2003-06-16 | 2006-03-29 | GlaxoSmithKline Biologicals S.A. | Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines |
US9364533B2 (en) | 2003-06-16 | 2016-06-14 | Glaxosmithkline Biologicals S.A. | Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines |
EP1638597B1 (en) * | 2003-06-16 | 2015-04-01 | GlaxoSmithKline Biologicals S.A. | Polyanionic peptides for stabilizing vaccines |
US8137681B2 (en) | 2003-06-16 | 2012-03-20 | Glaxosmithkline Biologicals, S.A. | Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines |
EP1963308A2 (en) * | 2005-11-28 | 2008-09-03 | Nabi Biopharmaceuticals | Method for making nicotine hapten |
EP1963308A4 (en) * | 2005-11-28 | 2010-12-15 | Nabi Biopharmaceuticals | Method for making nicotine hapten |
EP1849780A1 (en) * | 2006-04-21 | 2007-10-31 | De Staat der Nederlanden, vert. door de minister van VWS | Vaccine against nicotine addiction |
WO2007123400A1 (en) * | 2006-04-21 | 2007-11-01 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Vaccine against nicotine addiction |
WO2007131972A1 (en) * | 2006-05-12 | 2007-11-22 | Cytos Biotechnology Ag | Nicotine-carrier vaccine formulation |
EP1854478A1 (en) * | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
US9688812B2 (en) | 2006-05-15 | 2017-06-27 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9080014B2 (en) | 2006-05-15 | 2015-07-14 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
US11547667B2 (en) | 2007-10-12 | 2023-01-10 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
WO2011127989A1 (en) | 2010-04-15 | 2011-10-20 | Glaxosmithkline Biologicals S.A. | Nicotine conjugate vaccine |
WO2011151807A1 (en) | 2010-06-04 | 2011-12-08 | Pfizer Vaccines Llc | Conjugates for the prevention or treatment of nicotine addiction |
WO2012074773A1 (en) * | 2010-11-18 | 2012-06-07 | Nabi Biopharmceuticals | Personalized drug treatment methods |
US9303013B2 (en) | 2014-05-16 | 2016-04-05 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
WO2015173685A1 (en) | 2014-05-16 | 2015-11-19 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
US9475793B2 (en) | 2014-05-16 | 2016-10-25 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
AU2015264325B2 (en) * | 2014-05-19 | 2019-02-14 | The Scripps Research Institute | Enantiopure haptens for nicotine vaccine development |
US10487141B2 (en) | 2014-05-19 | 2019-11-26 | The Scripps Research Institute | Enantiopure haptens for nicotine vaccine development |
EP3145920A4 (en) * | 2014-05-19 | 2017-12-27 | The Scripps Research Institute | Enantiopure haptens for nicotine vaccine development |
CN106458971A (en) * | 2014-05-19 | 2017-02-22 | 斯克利普斯研究院 | Enantiopure Haptens For Nicotine Vaccine Development |
WO2019036419A1 (en) | 2017-08-15 | 2019-02-21 | Kalnik Matthew W | Novel nicotine-binding antibodies |
US11440970B2 (en) | 2017-08-15 | 2022-09-13 | Antidote Therapeutics, Inc. | Nicotine-binding antibodies |
WO2019236665A1 (en) | 2018-06-06 | 2019-12-12 | Antidote Therapeutics, Inc. | Methods for improving circulation and treating cardiovascular disease |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1135166B1 (en) | Hapten-carrier conjugates for treating and preventing nicotine addiction | |
EP1024834B1 (en) | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | |
US20100015172A1 (en) | Method to reduce the physiologic effects of drugs on mammals | |
JP6564396B2 (en) | Enantiopure hapten for nicotine vaccine development | |
JP2004517846A (en) | vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-396/01 Country of ref document: YU Ref document number: 99813956.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999964009 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20335/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2352765 Country of ref document: CA Ref document number: 2352765 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 512103 Country of ref document: NZ Ref document number: 200104477 Country of ref document: ZA Ref document number: 1020017006805 Country of ref document: KR Ref document number: IN/PCT/2001/00454/DE Country of ref document: IN Ref document number: 143474 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2000 584928 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/005511 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200100610 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/02411 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999964009 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017006805 Country of ref document: KR |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWG | Wipo information: grant in national office |
Ref document number: 20335/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999964009 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017006805 Country of ref document: KR |